Program Access and Details:

Program Length:
17 minutes

Resources:
Colchicine for coronary disease - teaching an old dog new tricks

Credits:
This program is not accredited. Physicians may earn self-learning credits through active steps.

Target Audience:
Family physicians, cardiovascular specialists, allied health professionals

This program was developed by the Canadian Collaborative Research Network.

Program Description:

Inflammation is known to play an important role in the pathogenesis of atherosclerosis. Colchicine, an anti-inflammatory drug, has now been tested in several large trials of patients with coronary artery disease. While these trials have shown overall benefit on CV outcomes, there has been a trend towards increased non-CV death with colchicine. This podcast will explore the potential benefits of colchicine in CAD vs. the potential risks, and discuss whether colchicine should become a guideline-endorsed therapy for patients with CAD.

Learning Objectives

1. To review the potential for colchicine to improve cardiovascular outcomes in patients with CAD
2. To explore the safety of colchicine on non-CV death

This program is NOT accredited.

Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.

Specialist participants may claim Section 2 credits (up to 2 credits per hour) following completion of a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio. 

This program was developed by the Canadian Collaborative Research Network, a not-for-profit physician organization.  No outside funding support was received for this program.